retatrutide triple agonist gip glp-1 glucagon phase 3 2025 Eli Lilly just announced striking results for retatrutide, an experimental “triple agonist” that acts on three gut-hormone targets at once. On the top dose, people lost an average of 28% Structural insights into the triple
Pay in 4 interest-free payments of $6.79 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Oct 30 - Nov 4










:max_bytes(150000):strip_icc()/Health-GettyImages-2112483848-f232847292154b6d84312e7f0cbf8e2c.jpg)
















